Reviewing bioAffinity Technologies (BIAF) and The Competition

bioAffinity Technologies (NASDAQ:BIAF) is one of 37 publicly-traded companies in the “Commercial physical research” industry, but how does it weigh in compared to its rivals? We will compare bioAffinity Technologies to related companies based on the strength of its earnings, analyst recommendations, profitability, dividends, risk, institutional ownership and valuation.

Profitability

This table compares bioAffinity Technologies and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
bioAffinity Technologies	-313.34%	-107.20%	-84.10%
bioAffinity Technologies Competitors	-262.61%	-20.94%	-12.23%

Analyst Ratings

This is a breakdown of recent ratings and price targets for bioAffinity Technologies and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioAffinity Technologies	0	0	0	0	N/A
bioAffinity Technologies Competitors	48	717	1029	24	2.57

As a group, “Commercial physical research” companies have a potential upside of 1.73%. Given bioAffinity Technologies’ rivals higher probable upside, analysts plainly believe bioAffinity Technologies has less favorable growth aspects than its rivals.

Risk and Volatility

bioAffinity Technologies has a beta of 3.93, indicating that its share price is 293% more volatile than the S&P 500. Comparatively, bioAffinity Technologies’ rivals have a beta of 5.95, indicating that their average share price is 495% more volatile than the S&P 500.

Institutional & Insider Ownership

1.6% of bioAffinity Technologies shares are owned by institutional investors. Comparatively, 51.1% of shares of all “Commercial physical research” companies are owned by institutional investors. 44.3% of bioAffinity Technologies shares are owned by insiders. Comparatively, 17.6% of shares of all “Commercial physical research” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares bioAffinity Technologies and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
bioAffinity Technologies	$2.53 million	-$7.94 million	-2.94
bioAffinity Technologies Competitors	$1.08 billion	$56.29 million	-2.36

bioAffinity Technologies’ rivals have higher revenue and earnings than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

bioAffinity Technologies rivals beat bioAffinity Technologies on 9 of the 10 factors compared.

About bioAffinity Technologies

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.